Le Lézard
Classified in: Oil industry, Science and technology

The Bifaciality of LONGi Solar's Bifacial PERC Cell Brakes World Record


BEIJING, Dec. 7, 2017 /PRNewswire/ -- The National Center of Supervision and Inspection on Solar Photovoltaic Products Quality (CPVT) issued an independent test report showing that LONGi Solar's bifacial PERC monocrystalline cells achieved a world record bifaciality of 82.15%.

LONGi Solar released its bifacial PERC monocrystalline module (Hi-MO2) at Shanghai SNEC 2017. The goal is to supply modules to meet the growing market demand for higher efficiency products and to the China Top-Runner Programs.

LONGi's Hi-MO2 features high power technology, high-energy yield and low LCOE. For LONGi Solar, Hi-MO2 is synonymous with high efficiency, bifacial power generation, and provides the launch point for the new era of highly efficient, bifacial PERC monocrystalline power generation technology.

Hi-MO2 captures the best features of LONGi's Hi-MO1 technology platform - low-degradation, high-power PERC technology - and combines them with the bifacial technology. In mass production, the efficiency of the front side exceeds 21.2%. Light reception of the backside can bring significantly additional energy yield. If the backside power yield increases the overall module efficiency by 10%, the power of bifacial PERC module can reach 330 watts for 60-cell module (300 watts from the front side), and 396 watts for 72-cell module (360 watts from the front side).

The bifacial PERC modules come with double glass lamination. Combined with low degradation mono PERC technology, Hi-MO2 offers first-year degradation below 2%, and the average annual degradation below 0.45% for 30 years - significantly better than conventional modules. Meanwhile, the adoption of a double-glass improves PID resistance and can extend the module life beyond 30 years.

"Hi-MO2 extends the advantages of monocrystalline PERC to the back side of the module, without increasing costs. Combined with higher power and higher energy yield, Hi-MO2 reduces LCOE and brings more benefits to the PV power plant investors," Li Wenxue, President of LONGi Solar said.

The successful launch of bifacial monocrystalline modules is a testament to the PV market's desire for high-efficiency, high-reliability and high-yield products, and a full recognition of LONGi Solar's constant innovation in monocrystalline PERC cell technology.

The bifaciality of bifacial PERC cells in the market is about 75%, and LONGi Solar's monocrystalline bifacial PERC cell has increased the bifaciality to an industry-leading 82.15%, which has not only enriched the application scenarios of PERC bifacial cells, but also improved cost performance in addition to higher energy yield.


 


These press releases may also interest you

at 23:05
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

at 23:03
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...



News published on and distributed by: